General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Us2.ai(SIGNIFICANT), Alleviant Medical(MODEST), Allysta Pharma(MODEST), AnaCardio(MODEST), Applied Therapeutics(MODEST), AstraZeneca Pharmaceuticals(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Boston Scientific (SIGNIFICANT), Eli Lilly(SIGNIFICANT), Impulse Dynamics(MODEST), Ionis Pharma(MODEST), Janssen Research & Development(SIGNIFICANT), Medscape/WebMD(SIGNIFICANT), Merck & Co., Inc.(MODEST), Novartis(SIGNIFICANT), Novo Nordisk(SIGNIFICANT), Radcliffe(MODEST), Biopeutics(MODEST), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Intellia Therapeutics(MODEST), Prosciento Inc(NONE), Recardio(NONE), ReCor Medical(NONE), Roche(NONE), Sanofi(NONE), Siemens Healthcare (NONE), Bristol Myers Squibb (NONE), CardioRenal (NONE), Quidel Corporation (MODEST), Alnylam Pharma (MODEST), CPC Clinical Research (MODEST) RESEARCH/RESEARCH GRANTS: Clinician Scientist Award (National Medical Research Council of Singapore)(SIGNIFICANT), Roche(SIGNIFICANT), Novo Nordisk (SIGNIFICANT) OTHER FINANCIAL BENEFIT: Us2.ai(SIGNIFICANT), Us2.ai(NONE)

View Full Disclosure